Takeda Continues Diversification By Hiring French COO From GSK
This article was originally published in The Pink Sheet Daily
GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a joint venture with Takeda competitor Daiichi Sankyo in 2012 to challenge Takeda’s primacy in the Japanese vaccines market.
You may also be interested in...
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
A new report from Informa's Meddevicetracker outlines the market drivers and competitive landscape for the carotid artery stents and embolic protection devices market.
More than 9,000 of the kits made by Aligned Medical Solutions have been recalled because they include a prefilled saline syringe that was the subject of a high-risk class I recall.